MindWalk Holdings (HYFT) Share-based Compensation (2024 - 2026)
MindWalk Holdings (HYFT) reported Share-based Compensation of $185907.0 for Q1 2026, up 277.02% year-over-year from $49309.9 in Q1 2025, and up 136.68% quarter-over-quarter from -$506777.9 in Q4 2025.
MindWalk Holdings (HYFT) Share-based Compensation (2024 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has 3 years of Share-based Compensation data on file, last reported at $185907.0 in Q1 2026.
- Share-based Compensation for Q1 2026 came in at $185907.0, up 277.02% year-over-year; the trailing twelve-month figure through Jan 2026 was $166.9 million (up 36213.73% YoY), and the FY2025 annual result was $1.1 billion, up 97237.98% from the prior year.
- Share-based Compensation grew to $185907.0 in Q1 2026 per HYFT's latest filing, from -$506777.9 in the prior quarter.
- Over five years, Share-based Compensation peaked at $166.5 million in Q2 2025 and troughed at -$506777.9 in Q4 2025.
- A 3-year average of $18.6 million and a median of $131670.4 in 2024 frame the typical range for Share-based Compensation.
- On a YoY basis, Share-based Compensation climbed as much as 95182.63% in 2025 and fell as far as 540.79% in 2025.
- A 3-year view of Share-based Compensation shows it stood at $114969.3 in 2024, then plunged by 540.79% to -$506777.9 in 2025, then soared by 136.68% to $185907.0 in 2026.
- Business Quant data shows HYFT's Share-based Compensation at $185907.0 in Q1 2026, -$506777.9 in Q4 2025, and $662284.6 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 305,000.00 |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 26.47 Mn |
| 10 | MindWalk Holdings | 166.20 Mn | 156.06 Mn | 1.78 | 185,906.98 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | 185,906.98 |
| Jan 31, 2026 | 185,906.98 |
| Oct 31, 2025 | -506,777.94 |
| Oct 31, 2025 | -506,777.94 |
| Jul 31, 2025 | 662,284.65 |
| Jul 31, 2025 | 662,284.65 |
| Apr 30, 2025 | 166.55 Mn |
| Apr 30, 2025 | 166.55 Mn |
| Jan 31, 2025 | 49,309.88 |
| Jan 31, 2025 | 49,309.88 |
| Oct 31, 2024 | 114,969.33 |
| Oct 31, 2024 | 114,969.33 |
| Jul 31, 2024 | 120,501.48 |
| Jul 31, 2024 | 120,501.48 |
| Apr 30, 2024 | 174,792.31 |
| Apr 30, 2024 | 174,792.31 |
| Jan 31, 2024 | 131,670.42 |
| Jan 31, 2024 | 131,670.42 |